In line with our previous findings that TRIP13 stabilizes EGFR and potentiates EGFR signaling in GBM [14], our current data demonstrated that TRIP13 expression alleviates osimertinib-induced paraptosis in GBM cells, thereby promoting resistance against osimertinib. Here, EGFR is linked to glioblastoma.